Vaccines remain the cornerstone of medical prevention and are highly effective in reducing
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …

Background Whether treatment during acute COVID results in protective efficacy against
long COVID incidence remains unclear. Objectives To assess the relationship between …

Introduction Nirmatrelvir-ritonavir (NMV-r) and molnupiravir (MOL) were developed as out-
patient anti-viral for mild COVID-19. There was limited data on their role in treating COVID …

Objectives A reappraisal of the validity of the conclusions of systematic reviews (SRs)
related to nirmatrelvir/ritonavir for the treatment of COVID-19. Methods An overview of SRs …

Introduction We compared the effectiveness and virological clearance (VC) at day 7 (T7)
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …

ABSTRACT Background Since December 2022, the Omicron variant has led to a
widespread pandemic in China. The study was to explore the safety and effectiveness of …

The impact of SARS-CoV-2 infections in children has fortunately been lower than what has
been seen in adults. However, even previously healthy children have developed severe …

Objectives Previous research reported inconsistent results on the efficacy of molnupiravir in
treating COVID-19. Moreover, efficacy was not assessed in the intended-use population …

Background Tixagevimab/cilgavimab (Tix/Cil) shows promise as a prophylactic treatment
against coronavirus disease 2019 (COVID-19) in solid organ transplant recipients (SOTRs) …

Background & Aims: Monoclonal antibodies cazirivimab and imdevimab are used as a
combination drug in the treatment of severe acute respiratory syndrome coronavirus-2 …